We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More
A bipartisan group of Senate and House members have introduced a bill that would require drugmakers to justify price rises of more than 10 percent. Read More
While the overall price of generics under Medicare Part D fell since 2010, hundreds of products experienced “extraordinary” price hikes of at least 100 percent, the U.S. Government Accountability Office said. Read More
The U.S. Department of Justice issued grand jury subpoenas to Taro Pharmaceuticals and two of the company’s senior officials over the pricing of its generics, the drugmaker revealed in an SEC filing. Read More
A federal judge rescinded his own verdict backing the FDA’s decision to not grant Ferring exclusivity for its bowel preparation drug Preponik, ruling that the agency must give the company five-years of retroactive exclusivity. Read More
A federal judge rendered Janssen’s composition patent for Remicade invalid, marking a loss for the company engaged in ongoing efforts to block biosimilar competition. Read More
The U.S. Judicial Panel on Multidistrict Litigation is consolidating price-fixing suits against generics maker Covis Pharmaceuticals for its heart drug Lanoxin. Read More
In response to criticism surrounding the price of its EpiPen, Mylan plans to sell a generic version of its allergy treatment for half the price. Read More